MGMT and neoplasm: The benefit from combined radio-chemotherapy was particularly significant among patients with MGMT promoter-methylated tumours, who displayed a median overall survival of 13.5 months compared to only 7.7 months in the radiotherapy group (HR = 0.53; p < 0.0001).